Prevalence of HPV types in cervical specimens from

Authors: Eileen F Dunne Nicola P Klein Allison L Naleway Roger Baxter Sheila Weinmann Karen Riedlinger Barbara Fetterman Martin Steinau Mariela Z Scarbrough Julianne Gee Lauri E Markowitz Elizabeth R Unger

Publish Date: 2013/01/05

Volume: 24, Issue: 2, Pages: 403-407

PDF Link

Abstract

Two human papillomavirus HPV vaccines are available to prevent cervical cancer One early measure of HPV vaccine impact would be a reduction in vaccinerelated HPV types HPV 6 11 16 or 18 or HPV 16 18 in cervical samples from young women We aimed to assess feasibility of specimen collection and baseline HPV prevalence in an integrated healthcare delivery systemResidual cervical specimens collected during routine cervical cancer screening 2006–2008 were retained consecutively from eligible females aged 11–29 years stratified by age group Specimens were evaluated for 37 HPV genotypes using the Roche Linear Array assayOf 10124 specimens submitted 10103 99  were adequate for HPV testing Prevalence of HPV 6 11 16 or 18 genotype was 114  overall and was the highest in the youngest age group 181  in the 11–19yearolds 125  in the 20–24yearolds and 70  in the 25–29yearoldsThe authors would like to acknowledge the important contributions of Charlie Chao and Kristine Bennett for assistance with identifying and shipping specimens and Jim Braxton and Suzanne Powell for assistance with the database and analysis This study was funded by CDC through America’s Health Insurance Plans AHIP contract number 200200200732

Keywords: